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Introduction
The primary manifestation of the antiphospholipid anti-
body syndrome (APS) is thrombosis, which forms the
core of the classification criteria for this syndrome.
However, multiple other noncriteria manifestations have
been attributed to APS, some of which do not appear to
have thrombosis as part of the pathophysiology,
although they may be mediated by autoantibodies.
Examples of these manifestations include neuropathy,
thrombocytopenia, and cardiac valvular disease. Of
importance, these manifestations of APS may not
respond well to anticoagulation, and therefore additional
therapies are needed.
Objectives
To describe a case report of a 12-years old boy with
severe isolated thrombocytopenia that was diagnosed as
antiphospholipid syndrome after an extended diagnostic
work-up.
Methods
Case report and review of the literature.
Results
We had a case of a 12-years old boy with severe isolated
thrombocytopenia (as low as 20.000/mm3) that was inves-
tigated for hematological diseases and previously treated
for a year for chronic immune thrombocytopenic purpura
without resolution with steroids. After an evaluation by a
rheumatologist, persistent high titers of IgM anticardioli-
pin, IgM anti-b2 glycoprotein, and positive lupus anticoa-
gulant were found.
A diagnosis of thrombocytopenia as an isolated mani-
festation related to antiphospholipid-syndrome was
made. There were no other remarkable symptoms, clini-
cal findings, laboratory tests or family history.
He presented a good initial response to corticosteroids,
but platelets decreased rapidly with dose reduction. He did
not show a good response to hydroxychloroquine. Treat-
ment with IVIg was started with very good response, but
platelet rapidly dropped to very low levels three weeks
after each infusion and no changes in antibody titers were
noted after six infusions. Rituximab (anti-CD20 monoclo-
nal antibody) was started and platelets increased rapidly a
month after infusion. After 10-months of a single dose of
rituximab, platelets are still high (300.000/mm3), anticar-
diolipin IgM and anti-b2 glycoprotein IgM titers are lower
than before. Immunoglobulin levels are still in the normal
range and CD19 and CD20 are low. Currently, he is on
hydroxychloroquine and aspirin.
Conclusion
Despite causing no substantial change in aPL profiles,
rituximab may be effective in controlling thrombocyto-
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